Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1703-1707

  Bozec, A ^a   Sudaka, A ^a   Toussan, N ^a   Fischel, J L ^a   Etienne Grimaldi, M C ^a   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cetuximab; Head and neck cancer; Irradiation; Sunitinib

Indexed keywords

CETUXIMAB; KI 67 ANTIGEN; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH NODE METASTASIS; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; THERAPY EFFECT; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; RADIOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349636351     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp070     Document Type: Article

References (24)

1. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
2. Bozec A, Formento P, Ciccolini J et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005; 4: 1962-1971.
3. Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-1465.
4. Jung YD, Mansfield PF, Akagi M et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38: 1133-1140.
5. Herbst RS, Mininberg E, Henderson T et al. Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCI as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur J Cancer 2003; 1: S293.
6. Wachsberger PR, Burd R, Marero N et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005; 11: 835-842.
7. Nieder C, Wiedenmann N, Andratschke N, Molls M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006; 32: 348-364.
8. Bozec A, Formento P, Lassalle S et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97: 65-72.
9. Bozec A, Sudaka A, Fischel JL et al. Combined effects of bevacizumab with erlotinib and irradiation: A preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008; 99: 93-99.
10. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
11. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35: 274-285.
12. Gridelli C, Maione P, Del Gaizo F et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12: 191-200.
13. Wang-Rodriguez J, Lopez JP, Altuna X et al. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006; 116: 1409-1416.
14. Bozec A, Lassalle S, Gugenheim J et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006; 95: 722-728.
15. Caponigro F, Formato R, Caraglia M et al. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 2005; 17: 212-217.
16. Meyerhardt J, Stuart K, Fuchs C et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2007; 18: 1185-1189.
17. Shirai K, O'Brien PE. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2007; 8: 239-251.
18. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: Rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 2007; 8: S79-S85.
19. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006; 16: 45-50.
20. Schmidt-Ullrich RK, Valerie K, Fogleman PB, Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996; 145: 81-85.
21. Goldman CK, Kim J, Wong WL et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiform pathophysiology. Mol Biol Cell 1993; 4: 121-133.
22. Bozec A, Thariat J, Bensadoun RJ, Milano G. Chemoradiotherapy in head and neck squamous cell carcinoma: Focus on targeted therapies. Cancer Radiother 2008; 12: 14-24.
23. Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006; 11: 274-284.
24. Arsene D, Galais MP, Bouhier-Leporrier K, Reimund JM. Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opin Biol Ther 2006; 6: 1175-1192.